LSI Europe的动态

"The AMIC procedure delivers superior patient outcomes compared with hand-minced autologous cartilage implantation." A prominent study from Behrendt et al., comparing the use of AMIC & MCI in treating chondral and osteochondral defects. Following mid-term analysis of 48 patients, the data indicates superior outcomes in pain reduction, knee function and quality of life for patients who received AMIC. We pride ourselves on working with best in class solutions like Chondro-Gide? from Geistlich Ortho, and we're always on the look out for independent data that demonstrates this. Reference: Behrendt, P., Eggeling, L., Lindner, A., von Rehlingen‐Prinz, F., Krause, M., Hoffmann, M. et al. (2024) Autologous matrix induced chondrogenesis provides better outcomes in comparison to autologous minced cartilage implantation in the repair of knee chondral defects. Knee Surgery, Sports Traumatology, Arthroscopy, 1–8. https://lnkd.in/eQY_Fd5M

Cali Biosciences Announces Publication of Successful Phase 2 Bunion Study Results in Journal of Foot and Ankle Surgery ? Cali Biosciences Co., Ltd. (hereinafter referred to as “Cali Biosciences”), a biotechnology company dedicated to the research and development of innovative drugs, announced publication of “Efficacy, Safety, and Pharmacokinetics of CPL-01, an Investigational Long-Acting Ropivacaine, in Bunionectomy: Results of a Phase 2b Study” in the current edition of the Journal of Foot and Ankle Surgery.?The article’s authors, Hanghang Tommy Xu, John Zimmerman, Todd Bertoch, Lee Chen, PJ Chen, and Erol Onel, confirmed that CPL?01 demonstrates safety and efficacy in this surgical model, adding to the already published literature on CPL-01 in abdominoplasty and Hernia Repair. Dr. Tommy Xu, lead author of the paper, commented, “This important study is the first demonstration of the success of CPL-01 in bony pain; combined with its prior success in soft-tissue pain, this should be critical in getting a broad label across multiple surgical models.”?Dr. John Zimmerman, the study’s lead PI, agreed and pointed the potential benefits to patients, stating, “Pain relief and opioid control in a model such as bunionectomy is so critical – getting folks up and out of bed and back to living a normal life.”?Dr. Erol Onel, the Chief Medical Officer of Cali Biosciences US, LLC, emphasized the novel active ingredient in CPL-01:?“While there are several long-acting local anesthetics based on bupivacaine currently available, CPL-01 is based on ropivacaine, which is believed to be safer.” PJ Chen, the CEO of Cali Biosciences, emphasized that “these results are incredibly encouraging and we are hopeful that our Phase 3 results will be as successful, leading to positive news from the Regulatory authorities.?We continue to firmly believe that Cali Biosciences is positioned to be a leader in the peri-operative space, with a suite of products that could help serve doctors and patients around the world.”?

There is increasing evidence that microstents are achieving substantial drops in IOP over a long period of time. Devices in various stages of development and commercialization have been able to maintain IOP below 15 mmHg and, in many instances, achieve IOP reductions of 30?to 40?percent. Given that these surgical procedures are relatively easy to perform and have minimal complications or aftercare, Market Scope sees momentum building for the paradigm shift that would mean earlier surgical intervention in glaucoma, as companies seek approval for standalone glaucoma procedures. Microstents capable of consistently achieving IOP in the range of 15 mmHg to 18 mmHg are most often targeting glaucoma patients in a mild stage of disease, including cataract surgery patients with mild glaucoma. The goal is a very safe and easy-to-perform surgical procedure that reduces or eliminates a patient’s needs for medication that controls IOP. The greatest adoption of microstents has been in the United States market, where implanted microstents have increased from 5 thousand in 2012 and are projected to grow to nearly 225 thousand in 2024. A decline in CMS microstent reimbursement beginning in 2022 created headwinds for device makers, but two factors will fuel healthy future growth in the market: Alcon, the world’s leading ophthalmic device company, driving sales of the Hydrus Microstent technology after acquiring Ivantis in 2021; and companies adding microstents designed for more advanced and standalone patients. Market Scope’s new “2024 Glaucoma Surgical Device Market Report” offers a comprehensive analysis of the current global market for glaucoma devices, as well as a discussion of important trends, an examination of upcoming products that will impact the market, and a review of other key factors shaping future success.? This new report offers a comprehensive analysis of the current global market for glaucoma devices, as well as a discussion of important trends, an examination of upcoming products that will impact the market, and a review of other key factors shaping future success.?Product demand is forecast in units and dollars, and market shares are analyzed by product category. Twenty-two market competitors are profiled, with discussion of their products, strategic market position, background, and outlook. To learn more about this report and request a sample: ?? https://bit.ly/24GlDev ?? [email protected] #Microstents #Glaucoma #Surgery #Device #Ophthalmology

It has been a while since my last post. I'd like to share a case that presents several intriguing anatomical and technical considerations, which I believe will stimulate valuable discussion within our LinkedIn community. This patient is a 59-year-old attorney who consulted several other surgeons and was advised to undergo a 3-level ACDF procedure. However, he approached us seeking ADR. Despite ongoing debates among spinal specialists at national meetings and on LinkedIn regarding the efficacy of ACDF versus motion-preserving options and claims of excellent post-ACDF motion, many patients, upon conducting basic research or using common sense, express a preference for motion-preserving techniques. Although this patient presented with significant disc degeneration at C5-6 and C6-7, as well as moderately advanced right C4-5 facet arthropathy, he did not experience significant axial pain and primarily complained of radiculopathy. This triad of C5-6 and C6-7 DDD, combined with C4-5 hypermobility and slippage, is a common presentation in my practice. In surgical practices where fusion remains prevalent or is the primary option under consideration, conversations about ACDF often start by considering a 2-level procedure. However, it's not uncommon for these discussions to expand to include a third level. The rationale behind this approach is often based on the likelihood that the additional level will require surgery in the near future, making it practical to include it in the current proposed procedure. In this case, I could have chosen from various discs like Mobi C, Prodisc C, or Simplify for C5-6 and C6-7 with good outcomes. However, more detailed planning was needed at C4-5. I carefully assessed slip, potential hypermobility, and the common C5 superior anterior endplate defect. While I used Prodisc C Vivo without a keel at the caudal segments, I opted for the legacy Prodisc C at C4-5 to neutralize the hypermobility concern and provide initial stable fixation with the large keel, given the C5 anterior defect, until bone ingrowth occurs post-surgery. Here's a question or informal survey for my colleagues: If you were presented with the same critical decision as this patient, facing the same pathology, and both options were offered by either an excellent fusion or an arthroplasty surgeon, which option would you choose and why? Thierry Dufour Alan H. Daniels, MD Lali Sekhon, MD PhD MBA Scott Hodges J. Alex Sielatycki Anton Jorgensen Mike Selby Ralph Mobbs Rao Prashanth Amir Vokshoor M.D. Jared Ament, MD, MPH, FAANS Dr. Marcelo Perocco Richard Guyer John Edwards Betsy Grunch, MD, FAANS, FACS Dr. Ardavan Ardeshiri Nelson Machin Arias M. D. Dr. med. Samir Smajic Philip Louie Venu Nemani, MD, PhD #spinesurgery #discreplacement #discarthroplasty #spinearthroplasty #spine #neurosurgery #spinesurgeon #neaurosurgeon #neckpain #neurosurgeon #centinelspine

Armen, I appreciate that you push the envelope on these types of cases. Please collect data. The problem is we still have very little on multilevel cases. Also very little data on how a TDR does long term with significant DDD and spondylosis as demonstrated here at C5/6 and C6/7. The data is Level III at best. All the level I data is for one and two level cases that do not have this level of DDD. It is not good science to extrapolate that data on to these cases. That being said, I am a fan of pushing the limits of TDR technology, I just want people to carefully collect prospective data and publish it. Personally, I would do an ACDF at C5/6 and C6/7 and would do a Prodisc SK (rather than the legacy) at C4/5 for the same reasons you stated. Keep up the great work, Pierce

Failure rates in limb salvage procedures remain high. But what if there was a better solution? Oxford Performance Materials, Inc. has developed a personalized 3D printed non-metallic solution that is mechanically like bone, osteoconductive, bacteriostatic, radiolucent and modifiable in the OR. With a long history of clinical use, this game-changing OsteoFabRX technology is defining the future of personalized orthopedic implantology. #orthopedicsurgery #sarcoma #3dprinting https://lnkd.in/eNsjgmdF

This 3,772 Equinoxe aTSA study is the largest to analyze risk factors for the two most common complications after aTSA: rotator cuff tears and aseptic glenoid loosening. A multivariate analysis identified the patient demographic and comorbidities as well the implant and operative factors statistically associated with the occurrence of rotator cuff tears and aseptic glenoid loosening after aTSA. (Rotator cuff tears were more likely to have previous shoulder surgery and small size glenoids; whereas, aseptic glenoid loosening were more likely to be younger (<62 years), have small-size glenoids, and have a nonhybrid glenoids). Additionally, polyethylene shelf age was not associated with the occurrence of either complication. Finally, these authors calculated odds ratios for specific patient cohorts with multiple risk factors to identify the patients with the greatest risk for each complication. Congratulations to these authors for this important study!

Revitalizing Mobility: Exploring the Global Knee Replacement Market Get To More: https://lnkd.in/gpY25zJu Reclaiming Movement, Restoring Lives: Enter the #dynamic realm of the global knee #replacement market, where cutting-edge surgical #techniques and innovative implant technologies converge to rejuvenate mobility and restore independence for millions worldwide. From minimally invasive procedures to advanced #materials, this market empowers individuals to overcome #debilitating knee conditions and #embark on a journey towards renewed #vitality and freedom of #movement. Aging Population, Rising Demand: Delve into the driving forces behind the global knee replacement market, as an aging #population and increasing prevalence of #osteoarthritis propel demand for joint #replacement procedures. With improvements in surgical outcomes and patient #satisfaction, knee replacement #surgery emerges as a transformative solution for enhancing quality of life and mitigating the impact of degenerative joint diseases on #individuals and #healthcare systems alike. Innovation Pathways to Optimal Functionality: Explore the frontier of innovation within the global knee #replacement market, where research and #development initiatives continually push the #boundaries of #orthopedic science. From #customized implants and robotic-assisted surgeries to regenerative therapies, the pursuit of optimal #functionality and longevity drives #advancements that redefine the standards of care, promising enhanced outcomes and improved patient #experiences in the evolving landscape of knee #replacement surgery. Key players in the global Knee Replacement Market: 1. Aesculap (US) Implants Systems LLC 2. Corin Group 3. DePuy Synthes Companies 4. Smith & Nephew, Inc. PLC 5. Stryker 6. Zimmer Biomet #KneeReplacement #Orthopedics #JointHealth #Mobility #Surgery #MedicalDevices #OrthopedicImplants #Osteoarthritis #HealthcareTechnology #AgingPopulation #OrthopedicSurgery #Rehabilitation #PatientCare #QualityOfLife #HealthcareIndustry

I am pleased to share that our systematic review and meta-analysis on dual-mobility implants in total hip arthroplasty (THA) has been published in the Journal of Clinical Orthopaedics and Trauma. This study offers a comprehensive comparison between dual-mobility (DM) and fixed-bearing (FB) implants in both primary and revision THA contexts. Our findings indicate that DM implants may offer significant advantages over FB implants, particularly in reducing the risk of dislocation and all-cause revision surgery. While the analysis suggests a tendency towards lower revision rates with DM implants, further research is needed to confirm these benefits over the long term. This work adds to the growing body of evidence supporting the use of DM designs, especially in high-risk patients or complex revision surgeries. For those interested in the outcomes and methodology, the article is accessible online, and I would be happy to discuss the implications of our findings further. https://lnkd.in/egcrBteT

We are happy to share that our latest article, "Long-term outcomes of 1,989 immediate implant-based breast reconstructions: an analysis of risk factors for failure and revision surgery", has been published in PRS! ?? Together with Annelotte van Bommel, Frederieke van Duijnhoven, Astrid Scholten, Carolien Smorenburg, Leonie Woerdeman, and Corstiaan Breugem, we assessed the incidence of revision surgery and reconstruction failure of an immediate implant-based breast reconstruction following nipple- or skin-sparing mastectomy (IBR) and identified risk factors predictive of these outcomes. We found that ? IBR only failed in 6.7% ?And a revision surgery was required in 60% of all breasts. ?? Risk factors for these outcomes were older age, post-mastectomy radiotherapy, smoking, higher weight of the mastectomy specimen or larger implant volume. ? BUT: a breast was present at end of a mean follow-up of 5.2 years in 93.3%!! This was even achieved in one procedure in 40%. ??? Protective factors were nipple preservation compared to resection and using a direct-to-implant approach for IBR. So the majority of the IBRs required revision surgery but almost half do not and failure rates are extremely low. ?? We advocate for always offering IBR to all eligible women undergoing mastectomy. Interested? Click on the link below for the full text. #plasticsurgery #breastcancer #mastectomy #breastreconstruction #immediate #IBR #breastimplant #longterm #revisionsurgery #failure #health #medical #pinkribbon #breastcancermonth Pink Ribbon Nederland Antoni van Leeuwenhoek Plastic and Reconstructive Surgery